A secreted sirtuin from Campylobacter jejuni contributes to neutrophil activation and intestinal inflammation during infection.

Histone modifications control numerous processes in eukaryotes, including inflammation. Some bacterial pathogens alter the activity or expression of host-derived factors, including sirtuins, to modify histones and induce responses that promote infection. In this study, we identified a deacetylase encoded by Campylobacter jejuni which has sirtuin activities and contributes to activation of human neutrophils by the pathogen. This sirtuin is secreted from the bacterium into neutrophils, where it associates with and deacetylates host histones to promote neutrophil activation and extracellular trap production. Using the murine model of campylobacteriosis, we found that a mutant of this bacterial sirtuin efficiently colonized the gastrointestinal tract but was unable to induce cytokine production, gastrointestinal inflammation, and tissue pathology. In conclusion, these results suggest that secreted bacterial sirtuins represent a previously unreported class of bacterial effector and that bacterial-mediated modification of host histones is responsible for the inflammation and pathology that occurs during campylobacteriosis.

Synthesis and Evaluation of Antimicrobial Biobased Waxes as Coating Materials.

The objective of this study was to synthesize and evaluate the efficacy of antimicrobial waxes to be used as both physical and biological protection to perishable fruits and vegetables. The existing wax materials used in postharvest coating applications do not provide this antimicrobial functionality. One class of such waxes was obtained by covalently linking quaternary ammonium compounds (QACs) featuring alkyl, benzyl, and stearyl ester hydrophobic side groups to the terminal position of a bromo stearyl ester. A second class was obtained by linking these QACs to the pendant hydroxyl group of an aliphatic diamide made of 12-hydroxystearic acid, stearic acid, and ethylene diamine. In total, six distinct structures having three different QAC groups were synthesized. Compounds containing QACs with C8 alkyl groups exhibited potent inhibition toward the growth of both bacteria and fungi. Notably, the complete inhibition of Penicillium italicum and Geotrichum candidum, two fungi detrimental to the postharvest quality of fruits, as well as the complete destruction of viable cells for Gram-positive and Gram-negative bacteria was observed when these organisms were incubated in contact with QAC waxes or dispersed in an aqueous system at a concentration of 1.0 mM. Comparatively, benzalkonium chloride with an alkyl chain length of 10 carbon can completely inhibit Staphylococcus aureus at a concentration of 1.44 mM. The properties of the attached hydrophobic groups appeared to exert a strong influence on antimicrobial activity presumably due to differences in molecular orientation, size, and differences among microbial cellular structures.

Successful anti-CD20 monoclonal antibody treatment of severe autoimmune hemolytic anemia due to warm reactive IgM autoantibody in a child with common variable immunodeficiency.

Autoimmune hemolytic anemia due to warm reactive IgM autoantibodies is unusual, severe, and often fails to respond to standard immunosuppressive therapies in both adults and children. A 6-year-old girl with common variable immunodeficiency had longstanding steroid dependent, splenectomy-unresponsive, warm IgM autoantibody-mediated autoimmune hemolytic anemia. Rituximab, a monoclonal antibody directed against CD20 antigen, was used to deplete B lymphocytes and reduce autoantibody production. She received a total of six doses of rituximab (375 mg/m2). Therapy was well tolerated, and B-lymphocytes were effectively depleted from the peripheral blood. The patient was completely tapered off glucocorticoids. The patient has remained off immunosuppressive agents for 16 months despite the return of B lymphocytes to the peripheral circulation. She continues to require IVIG. Early treatment with rituximab might be an option for patients with warm reactive IgM autoantibody-mediated autoimmune hemolytic anemia not responding to other treatments or experiencing untoward side effects from those treatments.